News | Cardiac Diagnostics | March 23, 2016

Tackling Cardiovascular Health Risks in College Football Players

Research gives clinicians comparative benchmarks for collegiate athletes' hearts

college football players, cardiovascular health risks, Texas A&M University, Stephen Crouse

Image courtesy of Texas A&M University

March 23, 2016 — Recent research published in The American Journal of Cardiology and led by Stephen Crouse, Ph.D., is shedding light on the healthy cardiac parameters and blood pressure levels of collegiate American-style football (ASF) athletes.

Crouse, professor of kinesiology and joint professor of internal medicine at Texas A&M University, and his colleagues in the Department of Health and Kinesiology and the Health Science Center College of Medicine, studied 80 incoming Texas A&M football players. Data was collected over three years as part of a pre-participation physical exam. The purpose was to describe heart characteristics and blood pressure values in collegiate ASF athletes compared with normal values.

“Before this study, there weren’t baseline comparative benchmarks for screening and follow up of incoming NCAA [National Collegiate Athletic Association] football players for cardiac anatomical variations, blood pressure, and training effect,” said John Erwin, III, M.D., associate professor of internal medicine and co-author of this research. “These results should serve as a basis to better define normal and abnormal findings in athletes’ hearts.”

“The aspect of health in athletes is a really important component of what we do here at Texas A&M,” Crouse added. “Even though performance is very important, health of the athletes is critical.”

The heart trains just like any other muscle — it grows larger the more the athlete exercises. However, in the non-athlete population, a larger heart and thicker muscle can be associated with the risk of cardiovascular disease.

Football athletes are known to have larger hearts because, in part, they are larger people. This study confirmed that, finding enlarged hearts and increased ventricular wall thickness. The key is to adjust the heart size by the size of the individual to see if such adjustment brings the heart back into a normal range. If not, that could indicate there is an enlargement that may not be healthy.

“Our study doesn’t really tell us much about how well these athletes are going to perform on the field,” Crouse said. “We don’t say anything about having a bigger heart making you a better athlete. All we’re trying to do is get information that will help us make health judgments and help the athletes be healthier.”

Another aspect of cardiac health is blood pressure, and the researchers measured the occurrence of high blood pressure in football players. Researchers found that 64 percent of the study participants had pre-hypertension, meaning their blood pressure was elevated above what is normal but not enough to be considered high blood pressure. The study shows it is possible the elevated blood pressure represents an adaptation to the high-intensity training and could be reversed at the end of training.

Still, the researchers see these results as confirming the importance of monitoring athletes’ blood pressure on a regular basis throughout their college athletic career and beyond.

“What we would like to be able to do as time goes on is to follow these athletes from year to year as they train in our program to really be able to document what happens to their heart structure and function as we go through their training throughout their collegiate career,” Crouse said. “Hopefully we will be able to follow them after that and maybe we can track and see if there are certain kinds of cardiac issues that can predict them not being healthy in the future.”

For more information: www.ajconline.org

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init